Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer
Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of nanoparticle
albumin-bound paclitaxel (nab-paclitaxel) plus S-1 as first-line treatment in Chinese
patients with advanced pancreatic ductal adenocarcinoma (PDA).